Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?

被引:60
|
作者
Nagy, Gyoergy [1 ,2 ]
van Vollenhoven, Ronald F. [3 ]
机构
[1] Semmelweis Univ, Fac Med, Dept Rheumatol, H-1023 Budapest, Hungary
[2] Semmelweis Univ, Fac Med, Dept Genet Cell & Immunobiol, H-1089 Budapest, Hungary
[3] Karolinska Inst, Unit Clin Therapy Res Inflammatory Dis ClinTRID, S-17176 Stockholm, Sweden
关键词
LOW DISEASE-ACTIVITY; ADALIMUMAB PLUS METHOTREXATE; DOUBLE-BLIND; INDUCTION THERAPY; CONTROLLED-TRIAL; PHASE-II; INFLIXIMAB; MONOTHERAPY; OPPORTUNITY; WINDOW;
D O I
10.1186/s13075-015-0707-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The advent of new medications and new treatment strategies for rheumatoid arthritis has made it possible to achieve remission in more patients than before. Furthermore, recent clinical trials and register studies suggest that some patients who initially required aggressive therapy may achieve biologic-free remission or even the ultimate goal of therapy, drug-free remission, resembling recovery. Here, we present a discursive review of the most important studies addressing these issues. Based on the overall results, it remains unclear if achieving biologic-free and drug-free remissions are primarily due to the natural course of the disease or to the early therapeutic intervention according to the 'window of opportunity' hypothesis. Although medication-free remission is only achievable in a small subset of patients, characterizing this patient cohort may provide important information about beneficial prognostic factors and the underlying mechanisms. In summary, in a subset of patients biologic-free and even drug-free remission can be achieved; pursuing these possibilities in practice may decrease the risk for long-term side effects and attenuate the economic burden of the disease.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [41] Remission in psoriatic arthritis-where are we now?
    Coates, Laura C.
    Conaghan, Philip G.
    D'Agostino, Maria Antonietta
    De Wit, Maarten
    FitzGerald, Oliver
    Kvien, Tore K.
    Lories, Rik
    Mease, Philip
    Nash, Peter
    Schett, Georg
    Soriano, Enrique R.
    Emery, Paul
    RHEUMATOLOGY, 2018, 57 (08) : 1321 - 1331
  • [42] Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
    Lurati, Alfredomaria
    Scarpellini, Magda
    Re, Katia Angela
    Marrazza, Mariagrazia
    Mazzocchi, Daniela
    Laria, Antonella
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [43] Moving towards IMPROVED drug-free remission
    Vivian P. Bykerk
    Nature Reviews Rheumatology, 2018, 14 : 191 - 192
  • [44] Moving towards IMPROVED drug-free remission
    Bykerk, Vivian P.
    NATURE REVIEWS RHEUMATOLOGY, 2018, 14 (04) : 193 - 194
  • [45] Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment
    Wevers-de Boer, Kirsten V. C.
    Heimans, Lotte
    Visser, Karen
    Schouffoer, Anne A.
    Molenaar, Esmeralda T. H.
    van Groenendael, Johannes H. L. M.
    Peeters, Andre J.
    Speyer, Irene
    Collee, Gerard
    Huizinga, Tom W. J.
    Allaart, Cornelia F.
    RHEUMATOLOGY, 2015, 54 (08) : 1380 - 1384
  • [46] ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION IN THE AVERT TRIAL: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Bykerk, V. P.
    Burmester, G. R.
    Combe, B. G.
    Furst, D. E.
    Huizinga, T. W. J.
    Wong, D. A.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 477 - 478
  • [47] ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION IN THE AVERT TRIAL: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
    Bykerk, Vivian
    Burmester, Gerd
    Combe, Bernard
    Furst, Daniel E.
    Huizinga, Tom
    Wong, Daniel
    Emery, Paul
    RHEUMATOLOGY, 2016, 55 : 97 - 98
  • [48] Rheumatoid arthritis in 2003: where are we now with treatment?
    Weinblatt, ME
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 94 - 96
  • [49] Biological therapy for rheumatoid arthritis: where are we now?
    Horton, Sarah C.
    Emery, Paul
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (01) : 12 - 18
  • [50] FREQUENT AND SUSTAINED DRUG-FREE REMISSION IN THE AUSTRALASIAN CML8 TRIAL OF IMATINIB WITHDRAWAL
    Ross, M.
    Branford, S.
    Seymour, J.
    Arthur, C.
    Schwarer, A.
    Dang, P.
    Goyne, J.
    Bartley, P.
    Field, C.
    Slader, C.
    Filshie, R.
    Mills, A.
    Melo, J.
    White, D.
    Grigg, A.
    Hughes, T.
    HAEMATOLOGICA, 2012, 97 : 74 - 75